Inclisiran treatment in coronary artery disease patients was associated with a 57% reduction in mean LDL-C at 12 months (P<0.05).
Cohort (n=40)
No
Does inclisiran reduce LDL-C in Japanese patients with coronary artery disease?
Inclisiran provides sustained LDL-C reduction of over 50% at 1 year with acceptable tolerability in real-world Japanese CAD patients.
p-value: p=<0.05
Background: Clinical trial results suggest inclisiran lowers low-density lipoprotein-cholesterol (LDL-C), but long-term real-world data in Japanese coronary artery disease (CAD) patients are limited. Methods and Results: We retrospectively studied 40 CAD patients treated with inclisiran and followed for 12 months, assessing LDL-C levels at baseline and every 3 months; endpoints were within-patient LDL-C change, MACE (exploratory), and safety. Mean LDL-C fell by 59%, 56%, and 57% at 3, 6, and 12 months, respectively (all P<0.05). Adverse reactions comprised 1 case of MACE and 1 of injection-site reaction over the 12 months. Conclusions: In this single-center cohort, inclisiran was associated with sustained LDL-C reductions and acceptable tolerability over 1 year.
Tsuda et al. (Wed,) conducted a cohort in Coronary artery disease (n=40). Inclisiran was evaluated on within-patient LDL-C change (p=<0.05). Inclisiran treatment in coronary artery disease patients was associated with a 57% reduction in mean LDL-C at 12 months (P<0.05).